SLC5A2 and type 2 diabetes mellitus: Sodium–glucose co-transporter 2 (SGLT2) inhibitor which decreases glucose re-absorption in the kidney and increases excretion via the urine is the new drug class for type 2 diabetes management with favorable safety profiles [3, 4], and is recommended as an option for treatment intensification after the failure of metformin [5].